MYELOID MICROENVIRONMENT REMODELING AND IFITM-RIG-I HYPERACTIVATION DRIVE AML-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, RATHER THAN CYTOTOXIC DEFICIENCY

EHA Library, Guangshuai Teng, 4208085

AML-INDUCED MACROPHAGE-TREG CROSSTALK CREATES A SELF-REINFORCING IMMUNOSUPPRESSIVE LOOP VIA CD44 AND TIM-3

EHA Library, Alicia Perzolli, 4208087

PROGNOSTIC VALIDATION OF POST CONSOLIDATION MEASURABLE RESIDUAL DISEASE AND CD34+CD38- ACUTE MYELOID LEUKEMIA STEM CELLS: TOOLS FOR CLINICAL INTERVENTION

EHA Library, Kasper Croese, 4208090

AGE-DRIVEN REMODELLING OF THE TRANSCRIPTOMIC CELL-CELL INTERACTION LANDSCAPE IN THE BONE MARROW NICHE OF TP53-AML PATIENTS

EHA Library, Rebecca Andersson, 4208093

MODELLING, DECIPHERING AND THERAPEUTIC TARGETING OF THE CD47–SIRPΑ AXIS IN THE PHAGOCYTIC NICHE OF ACUTE MYELOID LEUKEMIA

EHA Library, Chloé Terrier, 4208094

PRMT2 IS INVOLVED IN CYTOSKELETAL REMODELING AND JNK SIGNALING THROUGH VAV1 AND WASP INTERACTIONS IN ACUTE MYELOID LEUKEMIA

EHA Library, Denis MASNIKOV, 4208095

OVERCOMING GENETIC OR ADAPTIVE RESISTANCE TO MENIN INHIBITORS IN MUTANT NPM1 AML WITH NOVEL ‘DRUGGABLE’ TARGETS IDENTIFIED VIA NPM1A-TURBOID FUSION AND MASS SPECTROMETRY

EHA Library, Christopher Mill, 4208096

A NOVEL DECITABINE ANALOGUE WITH ENHANCED ANTI-LEUKEMIA ACTIVITY AND REDUCED TOXICITY IN VIVO

EHA Library, Irmela Jeremias, 4208099

INHIBITORS OF IRE1A ENHANCE VENETOCLAX ACTIVITY IN DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA

EHA Library, Orsola di Martino, 4208103

DEVELOPMENT AND VALIDATION OF AN RWD-BASED MACHINE LEARNING MODEL PREDICTING FEBRILE NEUTROPENIA WITH DAY-LEVEL ACCURACY IN PATIENTS WITH NEWLY DIAGNOSED AML UNDERGOING INTENSIVE CHEMOTHERAPY

EHA Library, Anna Mervaala-Muroke, 4208107

DISSECTING THE ROLE AND MODULATION OF TNF RECEPTOR SIGNALING IN ACUTE MYELOID LEUKEMIA

EHA Library, Sayantanee Dutta, 4208109

HARNESSING THE BONE MARROW STROMA IN AML: FAP-TARGETED COSTIMULATORY AGONISTS POTENTIATE T-CELL BISPECIFIC ANTIBODY ACTIVITY AND PRESERVE T-CELL FITNESS

EHA Library, Anne-Sophie Neumann, 4208110

DRUG REPURPOSING SCREENING IDENTIFIES NSC319726 AS A SELECTIVE ANTI-LEUKEMIC AGENT THAT TRIGGERS AN INTEGRATED STRESS RESPONSE-MEDIATED DEATH PROGRAM IN AML

EHA Library, Peiyao Jiang, 4208111

MESENCHYMAL STROMAL CELLS PROTECT ACUTE MYELOID LEUKEMIA CELLS FROM VENETOCLAX-INDUCED APOPTOSIS THROUGH A CD90-MEDIATED ADHESION PATHWAY

EHA Library, Marilena Ciciarello, 4208112

CSF3R MEDIATES VENETOCLAX RESISTANCE IN ACUTE MYELOID LEUKEMIA VIA ACTIVATION OF THE JAK-STAT PATHWAY

EHA Library, Zi-Yuan Nie, 4208113

TARGETING PFKFB4 TO DISRUPT ANTIOXIDANT HOMEOSTASIS AND OXPHOS DEPENDENCY IN ACUTE MYELOID LEUKEMIA

EHA Library, Aysegul Erdem, 4208115

UNRAVELLING THE MECHANISM OF CHEMORESISTANCE IN AML: THE ROLE OF ATF4-PPP1R15A AXIS

EHA Library, Vasiliki Pappa, 4208116

THERAPEUTIC EFFICACY AND SAFETY OF KIT-TARGETED APTAMER–MONOMETHYL AURISTATIN E CONJUGATE IN ACUTE MYELOID LEUKEMIA

EHA Library, Tingting Liu, 4208118

EFFECTS AND MECHANISTIC STUDY OF ARTESUNATE IN ACUTE MYELOID LEUKEMIA HARBORING SRSF2 P95H MUTATIONS

EHA Library, Jiaxin Cheng, 4208121

FOXC1 MEDIATES DRUG RESISTANCE AND MHC-II SUPPRESSION: A NOVEL DUAL MECHANISM IN RELAPSED/REFRACTORY AML

EHA Library, Xiaoxuan Lu, 4208122

C-TERMINAL CEBPA MUTATIONS IMPOSE A DOSE-DEPENDENT MYELOID DIFFERENTIATION BLOCKADE IN ISOGENIC IPSC-DERIVED AML MODELS

EHA Library, Antonio Benedetto Ventura, 4208124

SINGLE-HIT AND MULTI-HIT DNMT3A, TET2 AND ASXL1 MUTATIONS SHAPE DISTINCT PATHWAYS TO AML

EHA Library, Wencke Walter, 4208127

PATHOGENIC ROLE AND THERAPEUTIC IMPLICATIONS OF CYTOPLASMIC P53 AGGREGATES IN TP53-MUTATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

EHA Library, Tadashi Okamura, 4208129

SHIKONIN EXERTS ANTI-LEUKEMIC ACTIVITY AGAINST FLT3-ITD-MUTATED ACUTE MYELOID LEUKEMIA BY PROMOTING CBL-MEDIATED DEGRADATION OF THE FLT3 RECEPTOR

EHA Library, SuJun Gao, 4208130

SYSTEMIC REPROGRAMMING OF INFLAMMATORY MICROENVIRONMENT IN AML: FROM NETWORK PATTERNS TO PROGNOSTIC PREDICTION

EHA Library, Shuqing Wang, 4208132

DDX41-MUTATED MYELOID NEOPLASMS IN A LARGE CHINESE COHORT:DISTINCT GERMLINE HOTSPOTS, CLINICAL OUTCOMES, AND SUPERIOR RESPONSE TO HSCT

EHA Library, YUEQI SUN, 4208135

THE NOVEL LYSOSOME INHIBITOR LYS05 SYNERGIZES WITH VENETOCLAX TO EXERT ANTI-AML ACTIVITY BY NEGATIVELY REGULATING AUTOPHAGY

EHA Library, Xia Jiang, 4208136

PATIENT-INFORMED ENDOGENOUS KMT2A::ELL AND KMT2A::MLLT1 INFANT LEUKEMIA MODELS IN HUMAN HSPCS REVEAL FUSION-DEPENDENT LINEAGE STATES AND ACTIONABLE VULNERABILITIES

EHA Library, Álvaro Menchaca Muñiz, 4208137

SYNERGISTIC EFFICACY OF HDACI CHIDAMIDE WITH GL-V9 BY SUPPRESSING MYBL2 EXPRESSION IN ACUTE MYELOID LEUKEMIA

EHA Library, Zheng Ge, 4208138

CLINICAL AND MOLECULAR CHARACTERIZATION OF THERAPY-RELATED AML: INSIGHTS FROM THE HARMONY PLATFORM

EHA Library, Luca Guarnera, 4208140

REFINING PROGNOSTIC STRATIFICATION IN ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED GENE MUTATIONS ACCORDING TO VARIANT ALLELE FREQUENCY

EHA Library, Yu-Sung Chang, 4208141

CLINICAL AND TRANSCRIPTOMIC IMPACTS OF TET2 MUTATIONS IN DE NOVO ACUTE MYELOID LEUKEMIA: A MAJOR DETERMINANT OF SURVIVAL BEYOND CURRENT RISK MODELS

EHA Library, Tsung-Han Li, 4208143

PROGNOSTIC RISK INTEGRATION FOR SURVIVAL MODELING IN ACUTE MYELOID LEUKEMIA (PRISM-AML): A MULITNATIONAL COHORT STUDY

EHA Library, Curtis Lachowiez, 4208145

FLAG-IDA VERSUS VENETOCLAX-HMA AS SALVAGE THERAPY IN FIRST RELAPSED/REFRACTORY AML: REAL WORLD DATA

EHA Library, Gaspar Aspas Requena, 4208147

RUXOLITINIB AND DEXAMETHASONE COMBINATION THERAPY EFFECTIVELY PREVENTS DIFFERENTIATION SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Hongming Zhu, 4208149

ALIDHE: A PHASE 3B STUDY ASSESSING IVOSIDENIB + AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED MIDH1 ACUTE MYELOID LEUKAEMIA WHO ARE INELIGIBLE FOR INTENSIVE INDUCTION CHEMOTHERAPY

EHA Library, Paresh Vyas, 4208151

BEYOND BCL-2: QUANTITATIVE BCL-XL/MCL-1 AND BH3 PROTEIN PROFILING IDENTIFIES VENETOCLAX RESISTANCE IN ELDERLY AML PATIENTS

EHA Library, Chia-Jen Liu, 4208152

HMA PLUS VENETOCLAX FOR 7- VS 14- VS 21- VS 28-DAY CYCLES IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA: ELN- AND MAYO GENETIC RISK–STRATIFIED ANALYSIS IN 540 PATIENTS.

EHA Library, Naseema Gangat, 4208153

A PHASE 2 STUDY OF TAMIBAROTENE AND ARSENIC TRIOXIDE (ATO) FOLLOWED BY GEMTUZUMAB OZOGAMICIN (GO) FOR FIRST RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA: THE JALSG APL219R STUDY

EHA Library, Hiroto Ishii, 4208154

FLT3-ITD ALLELIC RATIO IS NO LONGER PROGNOSTIC IN AML PATIENTS TREATED WITH HIGH-DOSE ANTHRACYCLINE AND A FLT3 INHIBITOR

EHA Library, Mathieu Leclerc, 4208155

A NOVEL STRATEGY TO CIRCUMVENT VENETOCLAX RESISTANCE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA : UPDATED RESULTS FROM A PHASE II TRIAL

EHA Library, Huafeng Wang, 4208156

THE EFFICACY AND SAFETY OF THE DECITABINE, VENETOCLAX, AND SELINEXOR REGIMEN IN PATIENTS WITH NEWLY DIAGNOSED AML UNFIT FOR INTENSIVE CHEMOTHERAPY: A PROSPECTIVE, SINGLE-ARM CLINICAL STUDY

EHA Library, Shukai Qiao, 4208157

A PHASE 2 TRIAL OF THE BCL2 INHIBITOR FCN-338 IN COMBINATION WITH AZACITIDINE OR CHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY OR NEWLY DIAGNOSED AML

EHA Library, Yu Hu, 4208158

CLINICAL ACTIVITY OF REVUMENIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NUP98-REARRANGED ACUTE LEUKEMIAS

EHA Library, Ghayas Issa, 4208159

UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE IB INVESTIGATION OF THE LSD1 INHIBITOR IADADEMSTAT (ORY-1001) IN COMBINATION WITH AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED AML

EHA Library, Curtis Lachowiez, 4208160

IMPACT OF FLOW CYTOMETRY MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE AND VENETOCLAX (AZA-VEN)

EHA Library, Aarya Murali, 4208161

SAFETY, TOLERABILITY, AND PRELIMINARY ACTIVITY OF ROGOCEKIB IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID MALIGNANCIES: RESULTS FROM A PHASE 1/2 STUDY (CTX-712-CL-02)

EHA Library, Guillermo Garcia-Manero, 4208163

CLINICAL AND MOLECULAR FEATURES AND CLONAL EVOLUTION OF AML WITH KMT2A-PTD: CONCURRENT KMT2A-PTD AND FLT3-ITD MAY REFINE THE ELN 2022 RISK STRATIFICATION

EHA Library, Yi-Tsung Yang, 4208164

DISTINCT FLT3-ITD CLONAL EVOLUTION PATTERNS IN AML REFLECT PRE-EXISTING BIOLOGY AND INFLUENCE PROGNOSIS

EHA Library, Szu-Chi Yao, 4208165

GILTERITINIB RESUMPTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION VS BEST SUPPORTIVE CARE IN RELAPSED/REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A LANDMARK AND PROPENSITY-MATCHED COHORT STUDY

EHA Library, Harinder gILL, 4208170

ASSESSING MRD BY MFC POST-SCT REFINES RISK STRATIFICATION IN AML: LONG-TERM FOLLOW-UP OF A MULTICENTER PROSPECTIVE STUDY

EHA Library, Siqi Li, 4208172

CLINICAL CHARACTERISTICS AND PROGNOSTIC IMPACT OF TP53 DELETION/IDER(17)(Q10)T(15;17) IN ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Gen Qing, 4208174

THE ROLE OF ALLO-HSCT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN COMPLETE MRD-NEGATIVE REMISSION AFTER THE FIRST COURSE OF INDUCTION (RESULTS OF A RANDOMIZED STUDY)

EHA Library, Irina Lukianova, 4208175

PROGNOSTIC MODEL FOR NEWLY DIAGNOSED M4/M5 ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE IN THE REAL-WORLD

EHA Library, Dan Wang, 4208176

LARGE LANGUAGE MODEL-ENHANCED CLINICAL RECORD ANNOTATION SUPPORTS RISK STRATIFICATION AND OUTCOME ANALYSES FOR AML PATIENTS TREATED WITH VENETOCLAX/AZACITIDINE FRONTLINE THERAPY

EHA Library, Xin Wang, 4208178

REVUMENIB AS MAINTENANCE FOR AML FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Hannah Goulart, 4208181

VENETOCLAX-BASED THERAPY OR INTENSIVE CHEMOTHERAPY FOR THE FRONTLINE TREATMENT OF FIT PATIENTS WITH IDH1/2 MUTATION ACUTE MYELOID LEUKEMIA? A MULTI-CENTER, REAL-WORLD, COHORT STUDY

EHA Library, Guopan Yu, 4208182

VENETOCLAX COMBINED WITH MODIFIED INTENSIVE CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A PROPENSITY SCORE-MATCHED ANALYSIS

EHA Library, Qiaoyi Zhou, 4208185

SIPA1 DEFICIENCY IN HOST IMMUNE NICHE UNLOCKS ITS ANTI-AML ACTIVITY

EHA Library, Runqing Zhang, 4208084

DNMT3AR878H-MUTATED QUIESCENT LEUKAEMIA STEM CELLS ARE TARGETABLE BY COMBINED VENETOCLAX AND AZACITIDINE THERAPY OR CELL-CYCLE PRIMING IN NPM1C-FLT3ITD AML

EHA Library, Paniz Tavakoli Shirazi, 4208086

A DUAL STRATEGY FOR AML: CAR T CELLS DERIVED FROM A NOVEL, HIGH-AFFINITY ANTI-CLL-1 MONOCLONAL ANTIBODY AND SENSITIZATION BY A MENIN INHIBITOR

EHA Library, Shuhei Kida, 4208088

TARGETING MCL-1 WITH CARDIO-SAFE DEGRADER CT-03P EXERTS ACTIVITY IN AML AND OVERCOMES VENETOCLAX RESISTANCE

EHA Library, Bing Carter, 4208089

TRANSCRIPTIONAL REWIRING TO A MONOCYTIC STATE REVEALS THERAPEUTIC VULNERABILITIES IN MENIN INHIBITOR RESISTANCE AML

EHA Library, Lanpeng Chen, 4208091

A PREVIOUSLY UNRECOGNIZED ROLE OF HUMAN SKIN MESENCHYMAL STEM CELLS IN CHEMOTHERAPY RESPONSE OF ACUTE MYELOID LEUKEMIA STEM CELLS

EHA Library, Elory Leonard, 4208092

SH2B3 EXPRESSION PREDICTS SELINEXOR SENSITIVITY IN ACUTE MYELOID LEUKEMIA

EHA Library, Donghua Zhang, 4208097

EPIGENETIC REGULATION OF CD52 INFLUENCES THE EXPRESSION OF AKT AND MODULATES THE CELLULAR RESPONSE TO VENETOCLAX AND UPROSERTIB IN ACUTE MYELOID LEUKEMIA

EHA Library, Carlos Quero-Dotor, 4208098

ACUTE MYELOID LEUKEMIA–ASSOCIATED INFLAMMATION PROMOTES BLOOD–BRAIN BARRIER DISRUPTION AND NEUROINFLAMMATION

EHA Library, Oxana Bereshchenko, 4208100

INTEGRATIVE FUNCTIONAL SCREENING AND SINGLE-CELL LIPIDOMICS REVEAL METABOLIC ADAPTATION IN PU.1-DEFICIENT AML

EHA Library, Füsun Boydere, 4208101

OFF-THE-SHELF ENGINEERED INVARIANT NATURAL KILLER T CELLS (INKT CELLS) AS A NOVEL APPROACH FOR ACUTE MYELOID LEUKEMIA TREATMENT

EHA Library, Chaiyaporn Boonchalermvichian, 4208102

SPATIAL CHARACTERIZATION OF THE IMMUNE MICROENVIRONMENT IN BONE MARROW AND EXTRAMEDULLARY ACUTE MYELOID LEUKEMIA

EHA Library, Hossein Emami, 4208104

CASP1-EGR4 AXIS REGULATES MACROPHAGE REPOLARIZATION: A MECHANISTIC LINK TO IMMUNOSUPPRESSION IN AML

EHA Library, Liansheng Zhang, 4208105

NOVEL FRAGMENTATION ASSAY ENABLES COMPREHENSIVE FLT3‑INTERNAL TANDEM DUPLICATION DETECTION IN AML: AT DIAGNOSIS AND IN FOLLOW-UP

EHA Library, Lisanne Beugelink, 4208106

DUAL BET/HAT INHIBITOR–BASED COMBINATIONS EXERT SYNERGISTIC LETHALITY AGAINST MYELOPROLIFERATIVE NEOPLASMS (MPN) TRANSFORMED TO AML

EHA Library, Warren Fiskus, 4208108

ULTRA-DEEP NGS MRD ASSESSMENT AROUND HSCT FOR RELAPSE PREDICTION IN AML.

EHA Library, Carolina Martinez Laperche, 4208114

TARGETING INFLAMMATION VIA P38MAPK INHIBITION TO IMPROVE AZACITIDINE EFFICACY IN AGED AML

EHA Library, Ana Vitlic, 4208117

PROTEOMICS REVEALS HSP90-ENRICHED FERROEVS ASSOCIATED WITH SERIAL TRANSMISSION OF FERROPTOSIS IN AML CELLS

EHA Library, Hiroki Doi, 4208119

UNLOCKING VULNERABILITIES: BCL2 INHIBITORS TARGET BCOR-MUTATED AML

EHA Library, Sylvain Garciaz, 4208120

SINGLE-CELL LANDSCAPE OF CEBPANTERM-MUTATED ZEBRAFISH REVEALS PROGENITOR DIFFERENTIATION BLOCK AND GRANULOCYTE DYSREGULATION

EHA Library, Zhangjie Chen, 4208123

COMPUTATIONAL IDENTIFICATION OF A MONOCYTIC-METABOLIC VENETOCLAX-RESISTANT AML SUBTYPE WITH CDK INHIBITOR VULNERABILITY

EHA Library, Natalia Baran, 4208125

CHEMOTHERAPY MODULATES THE EPIGENETIC LANDSCAPE AND THE IMMUNE MICROENVIRONMENT IN MLL-AF9-DRIVEN ACUTE MYELOID LEUKAEMIA

EHA Library, Alessia Zangari, 4208126

ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE AND MYELODYSPLASIA-RELATED MUTATIONS: PROGNOSTIC IMPACT OF A PATHWAY-BASED STRATIFICATION

EHA Library, Guadalupe Oñate, 4208128

HMGN1 REGULATES THE TRANSCRIPTIONAL OUTPUT OF DIVERGENT HIF-1 REGULONS IN MLL-AF9- AND AML1-ETO-DRIVEN AML.

EHA Library, Gillian Caalim, 4208131

A MULTI-OMICS PLASMACYTOID DENDRITIC CELL SIGNATURE PREDICTS PROGNOSIS AND REFINES RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA

EHA Library, Xuan Wen, 4208133

SYNERGISTIC ANTI-LEUKEMIC EFFECTS OF HOMOHARRINGTONINE COMBINED WITH CLIFUTINIB IN FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Wenjie Sha, 4208134

FINAL ANALYSIS OF THE APOLLO TRIAL FOR HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL)

EHA Library, Maria Teresa Voso, 4208139

VENETOCLAX-AZACITIDINE IN COMBINATION WITH CHIDAMIDE AND CAG VERSUS "3+7" REGIMEN IN FIT OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA：A MULTICENTER, RANDOMIZED, PHASE 3 TRIAL

EHA Library, Zhenyang Gu, 4208142

RETROSPEKTIVE, MULTI-CENTER VALIDATION OF MAC-SCORING FOR PREDICTION OF HMA/VENETOCLAX RESPONSE

EHA Library, Alexander Waclawiczek, 4208144

DDX41-MUTATED ACUTE MYELOID LEUKEMIA DEFINES A DISTINCT AML ENTITY

EHA Library, Carolin Seeling, 4208146

REAL WORLD CHARACTERISTICS AND OUTCOMES IN A LARGE COHORT OF FIT PATIENTS WITH CBF-AML: A MULTINATIONAL PETHEMA-GPLA-ACHO-GRELAM STUDY

EHA Library, Evelyn Acuña-Cruz, 4208150

MRD-GUIDED TREATMENT WITH PEMBROLIZUMAB AND AZACITIDINE IN NPM1-MUTATED AML PATIENTS WITH IMMINENT HEMATOLOGICAL RELAPSE – RESULTS OF THE PROSPECTIVE PEMAZA TRIAL

EHA Library, Madlen Jentzsch, 4208162

MYELOID NEOPLASMS WITH PRDM16 VS. MECOM REARRANGEMENTS: THE FIRST AND LARGEST COMPARATIVE STUDY

EHA Library, Shaobin Yang, 4208166

FIRST-STAGE RESULTS OF SELINEXOR COMBINED WITH DECITABINE AND DOSE-ADJUSTED CMG (CYTARABINEÞ+MITOXANTRONE+G-CSF) IN VENETOCLAX-EXPOSED R/R AML: A PROSPECTIVE, SINGLE-ARM, MULTICENTER STUDY

EHA Library, Zi-Yuan Nie, 4208167

SPLICEOSOME MUTATIONS IDENTIFY AML PATIENTS AT HIGH RISK FOR ANTHRACYCLINE-INDUCED ATRIAL FIBRILLATION

EHA Library, Guangshuai Teng, 4208168

REAL-WORLD OUTCOMES IN MECOM-REARRANGED AML: THE LARGEST MULTICENTER COHORT REPORTED TO DATE

EHA Library, Cecilia Arana Yi, 4208169

REAL-WORLD TRANSFUSION INDEPENDENCE OUTCOMES WITH FRONTLINE IMETELSTAT VERSUS LUSPATERCEPT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Andres Ramirez-Gamero, 4208171

PHASE I/PHASE 2 STUDY OF QUIZARTINIB COMBINED WITH CLIA IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY FLT3-MUTATED AND WILD-TYPE ACUTE MYELOID LEUKEMIA

EHA Library, Musa Yilmaz, 4208173

ACUTE MYELOID LEUKEMIA (AML) PATIENT, DISEASE, AND MOLECULAR CHARACTERISTICS ASSOCIATED WITH A LONG-TERM RESPONSE TO OLUTASIDENIB

EHA Library, Stéphane De Botton, 4208177

LONG-TERM FOLLOW UP OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) PLUS VENETOCLAX IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A PHASE 2 STUDY

EHA Library, THURA WIN HTUT, 4208179

FRONTLINE LOW-INTENSITY VAH ACHIEVES HIGH MRD-NEGATIVE REMISSION RATES IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED AML

EHA Library, Yannan Jia, 4208180

REVUMENIB THERAPY POST HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH RELAPSED/REFRACTORY KMT2AR, NPM1M, AND NUP98R ACUTE MYELOID LEUKEMIA: POST HOC ANALYSIS OF OUTCOMES FROM AUGMENT-101

EHA Library, Andrius Žučenka, 4208183